Drug Information
| Drug General Information | Top | |||
|---|---|---|---|---|
| Drug ID |
D0B6RA
|
|||
| Former ID |
DCL000159
|
|||
| Drug Name |
LY404039
|
|||
| Synonyms |
LY 404039; LY-404039; (1R,2S,5R,6R)-2-amino-4,4-dioxo-4$l^{6}-thiabicyclo[3.1.0]hexane-2,6-dicarboxylic Acid; 4-amino-2-thiabicyclo(3.1.0)hexane-4,6-dicarboxylic acid
Click to Show/Hide
|
|||
| Drug Type |
Small molecular drug
|
|||
| Indication | Schizophrenia [ICD-11: 6A20] | Phase 3 | [1] | |
| Company |
Eli Lilly
|
|||
| Structure |
 |
Download2D MOL |
||
| Formula |
C7H9NO6S
|
|||
| Canonical SMILES |
C1C(C2C(C2S1(=O)=O)C(=O)O)(C(=O)O)N
|
|||
| InChI |
1S/C7H9NO6S/c8-7(6(11)12)1-15(13,14)4-2(3(4)7)5(9)10/h2-4H,1,8H2,(H,9,10)(H,11,12)/t2-,3-,4+,7+/m1/s1
|
|||
| InChIKey |
AVDUGNCTZRCAHH-MDASVERJSA-N
|
|||
| CAS Number |
CAS 635318-11-5
|
|||
| PubChem Compound ID | ||||
| PubChem Substance ID |
14794707, 24134022, 44932690, 57304381, 80695264, 99432360, 103505250, 104081980, 124757872, 125164675, 126580877, 126661301, 126667029, 126737985, 135207457, 136345853, 136367508, 136367894, 141563783, 144116158, 152344522, 162037996, 162202787, 162628953, 163621121, 163686460, 170481121, 174007058, 177748766, 184811962, 188899493, 198943115, 223677217, 227333337, 242585619, 248674929, 251963146, 251970940, 252215732, 252553578
|
|||
| ChEBI ID |
CHEBI:94640
|
|||
| Target and Pathway | Top | |||
|---|---|---|---|---|
| Target(s) | Metabotropic glutamate receptor 3 (mGluR3) | Target Info | Agonist | [2], [3], [4] |
| KEGG Pathway | Neuroactive ligand-receptor interaction | |||
| Glutamatergic synapse | ||||
| Cocaine addiction | ||||
| Panther Pathway | Heterotrimeric G-protein signaling pathway-Gi alpha and Gs alpha mediated pathway | |||
| Heterotrimeric G-protein signaling pathway-Gq alpha and Go alpha mediated pathway | ||||
| Ionotropic glutamate receptor pathway | ||||
| Metabotropic glutamate receptor group II pathway | ||||
| Reactome | G alpha (i) signalling events | |||
| Class C/3 (Metabotropic glutamate/pheromone receptors) | ||||
| WikiPathways | GPCRs, Class C Metabotropic glutamate, pheromone | |||
| GPCR ligand binding | ||||
| GPCR downstream signaling | ||||
| References | Top | |||
|---|---|---|---|---|
| REF 1 | ClinicalTrials.gov (NCT01487083) A Long-Term Study in Schizophrenia. U.S. National Institutes of Health. | |||
| REF 2 | Positive allosteric modulators of the metabotropic glutamate receptor 2 for the treatment of schizophrenia. Expert Opin Ther Pat. 2009 Sep;19(9):1259-75. | |||
| REF 3 | Glutamate and dopamine components in schizophrenia. J Psychiatry Neurosci. 2009 Mar;34(2):143-9. | |||
| REF 4 | Glutamate receptor mGlu2 and mGlu3 knockout striata are dopamine supersensitive, with elevated D2(High) receptors and marked supersensitivity to the dopamine agonist (+)PHNO. Synapse. 2009 Mar;63(3):247-51. | |||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.